Head-to-head evidence
APG-2575(Lisaftoclax ) vs Surzetoclax
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCL-2 · full Multiple Myeloma pipeline
APG-2575(Lisaftoclax )
Developed by Ascentage Pharma Group Inc.
NCT04674514 · Phase 1/2 · status unknown
This is a non-randomized, open-label dose-escalation study with no control group, primarily designed to establish a tolerable dose rather than to prove efficacy. Results have not yet been posted.
Surzetoclax
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2030 · NCT06953960 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APG-2575(Lisaftoclax )'s landscape · Surzetoclax's landscape